secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0001493152-23-007001
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera reports Q4 2022 rev $10.1M (+11% YoY); FY rev $28.7M (+19%); guides 25% growth in 2023
--------------------------------------------------------------------------------

- Total revenue Q4 2022 $10.1M (+11% YoY); FY 2022 $28.7M (+19% YoY).
- Net loss Q4 $2.8M vs $14.5M in Q4 2021; FY net loss $0.64M vs $37.7M in 2021.
- Adjusted EBITDA negative $4.4M in Q4 and negative $18.1M for FY 2022.
- Guidance: FY 2023 revenue growth at least 25%; expects cash flow positive within ~2 years.
- Expanding salesforce to 50-55 over next couple of years; will stop providing preliminary quarterly revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315223007001/0001493152-23-007001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315223007001/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-007001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer